Adaptin Bio shares approved for OTCQB quotation under ticker APTN

ADAPTIN BIO, INC.

Common shares approved for quotation on OTCQB Venture Market; ticker symbol APTN.
Trading expected to begin within the next 6-8 weeks, pending any material updates.
CEO notes lead program APTN-101 is expected to begin a Phase 1 first-in-human trial shortly.
Company develops precision cancer therapeutics targeting brain and difficult-to-reach tissues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.